Blog
RSS FeedPosted by Michael Wonder on 17 Oct 2016
FDA approves Genentech’s Lucentis (ranibizumab injection) pre-filled syringe
14 October 2016 - First anti-VEGF pre-filled syringe FDA approved to treat people with wet age-related macular degeneration and people ...
Posted by Michael Wonder on 15 Oct 2016
Health care law’s beneficiaries reflect its strengths, and its faults
14 October 2016 - Cara Suzannah Latil is living proof that the Affordable Care Act works — but also of ...
Posted by Michael Wonder on 15 Oct 2016
Insurers pay more for multiple sclerosis drug because rebates don’t help, report says
13 October 2016 - Drug makers may offer rebates to payers, but health plans continue to see notable increases in ...
Posted by Michael Wonder on 13 Oct 2016
Substantial rebates negotiated in Medicare Part D
12 October 2016 - A new QuintilesIMS Institute research brief takes a first-of-its-kind look at Part D costs after accounting ...
Posted by Michael Wonder on 12 Oct 2016
Undermining value-based purchasing — lessons from the pharmaceutical industry
12 October 2016 - In 2015, the U.S. Department of Health and Human Services announced a goal of linking at ...
Posted by Michael Wonder on 12 Oct 2016
Improved quality of Medicare health and drug plans means great news for Medicare beneficiaries
12 October 2016 - The Centers for Medicare & Medicaid Services is preparing for the annual Medicare Open Enrollment, which ...
Posted by Michael Wonder on 11 Oct 2016
ICER releases corrected evidence report on treatments for non-small-cell lung cancer
7 October 2016 - PD-1 value-based price benchmarks are updated while the main conclusions of the analysis remain unchanged. ...
Posted by Michael Wonder on 10 Oct 2016
Elbit Imaging announces that Gamida Cell has received FDA breakthrough therapy designation for Nicord
10 October 2016 - Elbit Imaging announced today that it was informed by Gamida Cell, an indirect associate of the ...
Posted by Michael Wonder on 10 Oct 2016
Anthem says will not cover Sarepta's approved Duchenne drug
7 October 2016 - Health insurer Anthem said it will not cover Sarepta Therapeutics Inc's medicine to treat patients with ...
Posted by Michael Wonder on 10 Oct 2016
U.S. FDA approves Carnexiv (carbamazepine) injection as intravenous replacement therapy for oral carbamazepine formulations
7 October 2016 - U.S. FDA approves Carnexiv (carbamazepine) injection as intravenous replacement therapy for oral carbamazepine formulations. ...
Posted by Michael Wonder on 09 Oct 2016
Coherus Biosciences announces FDA acceptance of 351(K) biologics license application to U.S. FDA for CHS-1701 (pegfilgrastim biosimilar candidate)
6 October 2016 - Coherus BioSciences today announced that the U.S. FDA has accepted the filing of 351(k) biologics license ...
Posted by Michael Wonder on 09 Oct 2016
Muscular dystrophy drug looks set for commercial success despite clinical doubts
3 October 2016 - A newly approved drug to treat Duchenne muscular dystrophy seems likely to be used by most ...
Posted by Michael Wonder on 06 Oct 2016
FDA grants breakthrough therapy designation for Roche’s Actemra/RoActemra in giant cell arteritis, a form of vasculitis
5 October 2016 - Fourteenth breakthrough therapy designation for Roche medicines. ...
Posted by Michael Wonder on 05 Oct 2016
Xenoscope, the revolutionary cost-effective laparoscope, wins FDA fast track clearance
4 October 2016 - Xenocor announced today that its first product, the Xenoscope, was 510(k) cleared by the U.S. FDA for ...
Posted by Michael Wonder on 03 Oct 2016
A golden ticket that fast tracks a medicine through the FDA
29 September 2016 - Sarepta Therapeutics won a big victory when its $300,000 muscular dystrophy drug was recently approved, but the ...